- Home
- FENC
as 01-17-2025 4:00pm EST
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 156.9M | IPO Year: | 2001 |
| Target Price: | $14.00 | AVG Volume (30 days): | 73.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.96 - $11.49 | Next Earning Date: | 11-07-2024 |
| Revenue: | $49,348,000 | Revenue Growth: | 278.09% |
| Revenue Growth (this year): | 170.43% | Revenue Growth (next year): | 6.70% |
Stock Insider Trading Activity of Fennec Pharmaceuticals Inc. (FENC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Raykov Rosty | FENC | Director | Jan 6 '25 | Sell | $6.08 | 10,000 | $60,800.00 | 91,432 | |
| Raykov Rosty | FENC | Director | Dec 5 '24 | Sell | $6.04 | 796 | $4,807.84 | 91,432 | |
| RALLIS CHRIS A | FENC | Director | Dec 2 '24 | Sell | $6.14 | 6,409 | $39,351.26 | 52,214 | |
| Raykov Rosty | FENC | Director | Dec 1 '24 | Sell | $6.13 | 1,635 | $10,022.55 | 91,432 | |
| Raykov Rosty | FENC | Director | Oct 31 '24 | Sell | $4.31 | 2,431 | $10,477.61 | 91,432 |
Latest Fennec Pharmaceuticals Inc. News
FENC Breaking Stock News: Dive into FENC Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Fennec Pharmaceuticals Gets Institute's Nod for Pediatric Hearing Loss Drug in England, Wales
MT Newswires
a month ago
Fennec Gets "Positive Recommendation" for Pedmarqsi Use in England and Wales
GlobeNewswire
a month ago
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
MT Newswires
a month ago
Fennec Pharmaceuticals Makes Early Partial Repayment of Convertible Debt Facility With Petrichor
MT Newswires
a month ago
Fennec Pharmaceuticals Partially Repays Convertible Debt Facility
GlobeNewswire
a month ago
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management
GlobeNewswire
a month ago
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
GlobeNewswire
2 months ago
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
Compare FENC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FENC Fennec Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.